Invitrogen Closes $391M Dynal Acquisition

Apr 01, 2005

NEW YORK, April 1 (GenomeWeb News) - Invitrogen closed its acquisition of privately held Dynal Biotech in a deal valued at approximately $391 million, the company said today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Already have an account?
Login Now.

Breaking News

RNA-Editing Protein ADAR Promotes Progression of Lung Cancer, New Study Finds
Biognosys, Waters Ink Comarketing Deal for DIA Mass Spec Tech
Researchers Identify SNP Set, Develop QR Code to Distinguish Genome Samples
Exosome Diagnostics Launches Evidence Development Study for Prostate Cancer Test
BioReference, The Garage Form Alliance to Advance Patient Care
Molecular Devices, Cytena Partner on Launch of Single-Cell Printer System

The Scan

Best Options

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

A Butterfly's Wings

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

This Week in PNAS

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Pathogen Tracking

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.

Main menu